Je. Anderson et al., Degradation of maternal Cdc25c during the maternal to zygotic transition is dependent upon embryonic transcription, MOL REPROD, 60(2), 2001, pp. 181-188
To gain a better understanding of the molecular differences that may contri
bute to cleavage arrest and the poorer development associated with laborato
ry produced embryos, a series of experiments were conducted to quantitate t
he message levels of the cell cycle controller cdc25c, over the maternal to
zygotic transition (MZT) in 4-cell in vivo- and in vitro-derived porcine e
mbryos. The experiments were designed to measure both maternal and embryoni
c derived cdc25c transcripts by quantitative reverse transcription-competit
ive polymerase chain reaction (RT-cPCR), determine the point of the transit
ion to zygotic genome activation, and study the interaction between initial
embryonic transcription and maternal cdc25c degradation. Analysis of in vi
vo- and in vitro-derived embryos revealed no difference in cdc25c message l
evel for any of the times P4CC (P > 0.05). Comparison of control embryos fr
om 5- to 33-hr P4CC revealed a reduction in transcript quantities in the 10
-hr P4CC group that was maintained at later time points (P < 0.05). Embryos
cultured in the RNA polymerase inhibitor, <alpha>-amanitin, from cleavage
to 5-, 10-, 18-, 25-, or 33-hr P4CC displayed no difference in cdc25c level
s when compared to controls at similar time points (P > 0.05). However, if
embryos were first exposed to alpha -amanitin after 18-hr P4CC with this tr
eatment continuing to 33 hr, the levels of cdc25c transcript were reduced (
P<0.04) when compared to those embryos that were first exposed to the inhib
itor at either 5- or 10-hr P4CC. This finding and the comparison of these s
ame embryos to the 0-33-hr <alpha>-amanitin and control groups allowed us t
o conclude that cdc25c transcription began between 10- and 18-hr P4CC, with
the degradation of maternal cdc25c message dependent on transcriptional in
itiation. Mol. Reprod. Dev. 60: 181-188, 2001. (C) 2001 Wiley-Liss, Inc.